Skip to main content
Clinical Trials/EUCTR2019-004999-19-DK
EUCTR2019-004999-19-DK
Active, not recruiting
Phase 1

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppressed HIV infection: A randomized open-label superiority trial. The AVERTAS-1 trial - AVERTAS-1

Department of infectious diseases, Hvidovre Hospital0 sites95 target enrollmentFebruary 14, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of infectious diseases, Hvidovre Hospital
Enrollment
95
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 14, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Department of infectious diseases, Hvidovre Hospital

Eligibility Criteria

Inclusion Criteria

  • \- Individuals \= 18 years old with
  • \- Diagnosed HIV and
  • \- At least 6 months of ongoing treatment with dolutegravir/ abacavir/lamivudine prior to inclusion
  • \- No pre\-existing viral resistance mutations to lamivudine or to dolutegravir
  • \- Plasma viral load (HIV\-RNA) \< 50 copies/ml
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 80
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • \- Pre\-existing viral resistance mutations to lamivudine or to dolutegravir
  • \- Presence of hepatitis B antigen (HBsAg) or HBV DNA
  • \- Cancer within past 5 years
  • \- Pregnancy or breastfeeding
  • \- Any case of diabetes or cardiovascular disease must be stable as assessed by the treating physician
  • \- Women of reproductive potential will be included if using approved contraception

Outcomes

Primary Outcomes

Not specified

Similar Trials